
Adascale Gel
Adapalene is a topical retinoid medication primarily used to treat acne vulgaris, a common skin condition caused by clogged pores, bacteria, and inflammation. It belongs to a class of compounds similar to vitamin A and works by speeding up skin cell turnover and clearing blocked pores.
How Adapalene Works
- Adapalene binds to retinoic acid receptors in the skin, helping regulate how skin cells grow and shed. This reduces clogged pores and prevents acne formation.
- It reduces inflammation, helping both non-inflammatory (whiteheads, blackheads) and inflammatory (red pimples) acne to improve over time.
- Compared to older retinoids, adapalene tends to cause less irritation and is more chemically stable in sunlight.
Dermapolis
Dermapolis is a skincare and derma pharma company in India that develops and markets dermatological products, including adapalene formulations.
About the Company
-
Dermapolis focuses on science-backed dermatology solutions for various skin concerns like acne, dryness, pigmentation, and sun protection.
-
Their products are dermatologist-tested and formulated for safety and effectiveness across different skin types.
Adapalene Products from Dermapolis
Dermapolis includes adapalene in several of its product offerings, designed to address acne and related concerns:
-
ADASCALE™ – Contains Adapalene 0.1% gel, targeting acne.
-
ADASCALE™-C – Combines Adapalene 0.1% + Clindamycin 1% for dual acne action.
-
ADASCALE™-B – Contains Adapalene 0.1% + Benzoyl Peroxide 2.5%, combining retinoid action with antibacterial effects.
Conclusion
Adapalene is an effective, widely used topical retinoid, especially for acne management. Its benefits include promoting clearer skin, reducing inflammation, and helping prevent future breakouts, with a generally tolerable side effect profile.
Companies like Dermapolis integrate adapalene into their derma products — such as ADASCALE™ gels — aiming to offer dermatologist-trusted acne solutions within a broader skincare portfolio.





Reviews
There are no reviews yet.